Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Virginia: - VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
- Virginia Commonwealth University Massey Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommende…
Sponsor: Immatics US, Inc.
NCT ID: NCT06743126
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia
Phase 3 Recruiting Industry
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Sponsor: Immunocore Ltd
NCT ID: NCT06112314
Sites in Virginia: - UVA Health-UVA Emily Couric Clinical Cancer Center — Charlottesville, Virginia
- Virginia Commonwealth University (VCU) - Massey Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Sponsor: IDEAYA Biosciences
NCT ID: NCT07015190
Sites in Virginia: - Augusta Health, Center for Cancer and Blood Disorders — Fishersville, Virginia
Phase 3 Recruiting Industry
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unr…
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05727904
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia
Phase 3 Recruiting Industry
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with …
Sponsor: Philogen S.p.A.
NCT ID: NCT03567889
Sites in Virginia: - VCU - McGlothlin Medical Education Center — Richmond, Virginia
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Virginia: - Inova Alexandria Hospital — Alexandria, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
Phase 2 Recruiting NIH
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05111574
Sites in Virginia: - VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Virginia: - Research Site 102 — Fairfax, Virginia
- Research Site 112 — Fairfax, Virginia
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Virginia: - Next Oncology Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Virginia: - USA05-0 — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Virginia: - Clinical Trial Site — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of re…
Sponsor: Georgiamune Inc
NCT ID: NCT06425926
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- b…
Sponsor: Aminex Therapeutics, Inc.
NCT ID: NCT07287917
Sites in Virginia: - Virginia Cancer Specialists-Fairfax — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Sponsor: ImmVira Pharma Co. Ltd
NCT ID: NCT04370587
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
NCT ID: NCT07115043
Sites in Virginia: - Research Site — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid …
Sponsor: Ipsen
NCT ID: NCT06305247
Sites in Virginia: - Virginia Cancer Specialist — Fairfax, Virginia
Phase 2 Recruiting Industry
Researchers want to learn if intismeran autogene with pembrolizumab can stop advanced melanoma from growing or spreading. Melanoma is a type of skin cancer. Advanced means the cancer has spread to other parts of the body and cannot be remo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06961006
Sites in Virginia: - Inova Schar Cancer Institute ( Site 4046) — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered …
Sponsor: OncoResponse, Inc.
NCT ID: NCT06090266
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will i…
Sponsor: IO Biotech
NCT ID: NCT05280314
Sites in Virginia: - Massey Cancer Center — Richmond, Virginia
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Virginia: - NEXT Oncology Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent adva…
Sponsor: Nested Therapeutics, Inc
NCT ID: NCT06326411
Sites in Virginia: - NEXT Oncology - Virginia — Fairfax, Virginia